Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: MORF4L1

Summary for MORF4L1

Gene information	Gene symbol	MORF4L1
	Ensembl ID	ENSG00000185787
	Entrez ID	10933
	Gene name	mortality factor 4 like 1
	Synonyms	Eaf3\|HsT17725\|MEAF3\|MORFRG15\|MRG15
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: MORF4L1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.267713	4.74e-14
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Progenitors	0.542778	5.95e-03
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.327738	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.256116	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.271026	3.48e-39
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.259996	2.18e-38
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-0.343072	1.32e-18
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.571663	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	0.25276	2.84e-04
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	-0.309246	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	0.305408	1.46e-06
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.381203	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.331243	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.606188	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.446569	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.571767	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.274177	6.50e-13
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.284494	4.40e-14
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.321651	1.38e-23
GSE104987	MCF7 cell line	Cell line	Breast cancer	ER+ breast cancer	Targeted therapy	KDM5-C70	NA	Malignant cells	-0.335608	5.21e-23
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.328073	3.81e-20
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	0.499504	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.393788	5.04e-44
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	0.668896	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	0.665447	0.00e+00

Top

Expression of MORF4L1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to MORF4L1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating MORF4L1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
MORF4L1	hsa-miR-203a-3p	98.1442	NM_001265603
MORF4L1	hsa-miR-498-3p	96.9634	NM_001265605
MORF4L1	hsa-miR-767-5p	95.5258	NM_001265603
MORF4L1	hsa-miR-6807-5p	94.2966	NM_001265603
MORF4L1	hsa-miR-676-5p	93.6067	NM_001265603
MORF4L1	hsa-miR-6744-5p	92.7111	NM_001265603
MORF4L1	hsa-let-7c-3p	92.527	NM_001265603
MORF4L1	hsa-miR-6501-3p	90.9207	NM_001265603
MORF4L1	hsa-miR-96-5p	90.0972	NM_001265603
MORF4L1	hsa-miR-29c-3p	89.0733	NM_001265603
MORF4L1	hsa-miR-29b-3p	89.0733	NM_001265603
MORF4L1	hsa-miR-29a-3p	89.0733	NM_001265603
MORF4L1	hsa-miR-4789-5p	88.6482	NM_001265603
MORF4L1	hsa-miR-570-3p	87.925	NM_001265603
MORF4L1	hsa-miR-12133	87.3339	NM_001265603
MORF4L1	hsa-miR-1271-5p	87.3339	NM_001265603
MORF4L1	hsa-miR-3180-5p	87.1349	NM_001265603
MORF4L1	hsa-miR-574-5p	86.7921	NM_001265603
MORF4L1	hsa-miR-1255a	85.9459	NM_001265603
MORF4L1	hsa-miR-1255b-5p	85.9459	NM_001265603
MORF4L1	hsa-miR-96-3p	85.6505	NM_001265603
MORF4L1	hsa-miR-7159-5p	83.9629	NM_001265603
MORF4L1	hsa-miR-4503	82.972	NM_001265603
MORF4L1	hsa-miR-6835-3p	81.658	NM_001265603

Page: 1

Top

Motifs and transcription factors (TFs) regulating MORF4L1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
MORF4L1	homer__TWVGGTCCGC_HINFP	HINFP (directAnnotation).
MORF4L1	transfac_pro__M06526	ZNF555 (directAnnotation).
MORF4L1	jaspar__MA0748.2	YY2 (directAnnotation).
MORF4L1	transfac_public__M00039	CREB1 (directAnnotation).
MORF4L1	transfac_pro__M00691	ATF1 (directAnnotation).
MORF4L1	jaspar__MA0039.4	KLF4 (directAnnotation).
MORF4L1	taipale_cyt_meth__KLF3_NRCCGCAGCCCN_FL_meth_repr	KLF3 (directAnnotation).
MORF4L1	tfdimers__MD00457	SREBF1; SREBF2; ZNF354C (directAnnotation).
MORF4L1	transfac_pro__M04595	SALL2 (directAnnotation).
MORF4L1	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_repr	ZNF385D (directAnnotation).
MORF4L1	jaspar__MA1125.1	ZNF384 (directAnnotation).
MORF4L1	transfac_pro__M05513	ZNF641 (inferredBy_Orthology).
MORF4L1	kznf__ZNF384_Schmitges2016_RCADE	ZNF384 (directAnnotation).
MORF4L1	transfac_pro__M06135	ZNF28 (directAnnotation).
MORF4L1	hocomoco__GSC2_HUMAN.H11MO.0.D	GSC2 (directAnnotation).
MORF4L1	hocomoco__TYY2_HUMAN.H11MO.0.D	YY2 (directAnnotation).
MORF4L1	metacluster_141.6	MZF1; TAF1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZNF597 (directAnnotation). TAF1; TAF1L (inferredBy_Orthology).
MORF4L1	taipale__YY2_DBD_NNCCGCCATNW_repr	YY2 (directAnnotation).
MORF4L1	metacluster_141.4	GLIS2 (directAnnotation).
MORF4L1	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_meth	ZNF385D (directAnnotation).
MORF4L1	jaspar__MA1460.1	YY1 (inferredBy_Orthology).
MORF4L1	metacluster_101.3	MYB (directAnnotation).
MORF4L1	flyfactorsurvey__pho_SOLEXA_F1-3	YY1 (inferredBy_Orthology).
MORF4L1	metacluster_34.3	EGR1; ETS1; SETDB1; SIX5; SIX5; ZNF143; ZNF76 (directAnnotation).
MORF4L1	metacluster_33.8	BRCA1; CHD2; CHD2; ETS1; NR3C1; ZBED1; ZBED1; ZBED1; ZBTB33; ZBTB33; ZBTB33; ZBTB33; ZBTB33; ZBTB33; ZBTB33 (directAnnotation). CHD2; ZBTB33 (inferredBy_Orthology).
MORF4L1	metacluster_45.6	E2F1; E2F1; E2F1; E2F1; E2F1; E2F2; E2F2; E2F2; E2F3; E2F3; E2F3; E2F4; E2F4 (directAnnotation). E2F2; E2F3 (inferredBy_Orthology).
MORF4L1	taipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNNNNNNCGGAAGN_CAP_repr	E2F1; ELK1 (directAnnotation).
MORF4L1	metacluster_172.6	CHD2; E2F1 (directAnnotation).
MORF4L1	stark__RCGCMATTW	YY1 (inferredBy_Orthology).
MORF4L1	transfac_pro__M05893	ZNF676 (directAnnotation).
MORF4L1	taipale_tf_pairs__E2F1_EOMES_RGGTGTNNNGGCGSNNTNNCRSNN_CAP	E2F1; EOMES (directAnnotation).
MORF4L1	metacluster_141.9	TAF1; YY1; YY1 (directAnnotation).
MORF4L1	taipale_cyt_meth__ZBTB2_NTTTMCGGTWAN_eDBD	ZBTB2 (directAnnotation).
MORF4L1	metacluster_135.10	MBD2; MBD2; MECP2; MECP2 (directAnnotation).
MORF4L1	metacluster_144.3	ZNF704; ZNF704 (directAnnotation).
MORF4L1	kznf__ZNF730_Imbeault2017_RP_RCADE	ZNF730 (directAnnotation).
MORF4L1	metacluster_141.5	NR3C1; THAP1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZNF597 (directAnnotation). YY1; YY1; YY1; YY2; ZFP42 (inferredBy_Orthology).
MORF4L1	metacluster_151.1	KAT7; PML; SMAD5; TAF1; ZFP37; ZGPAT; ZNF519; ZNF519; ZNF571; ZNF770; ZNF770; ZNF770; ZSCAN22; ZSCAN22 (directAnnotation).
MORF4L1	metacluster_175.1	ZNF283 (directAnnotation).
MORF4L1	metacluster_133.1	ZNF304; ZNF304; ZSCAN22 (directAnnotation).
MORF4L1	transfac_pro__M01219	SP1 (directAnnotation). SP3 (inferredBy_Orthology).
MORF4L1	transfac_pro__M04862	NRF1 (directAnnotation).
MORF4L1	taipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNCGGAAGN_CAP_repr	E2F1; ELK1 (directAnnotation).
MORF4L1	transfac_pro__M00492	STAT1 (directAnnotation).
MORF4L1	transfac_pro__M02913	SP140 (inferredBy_Orthology).
MORF4L1	transfac_pro__M01090	SMAD9 (inferredBy_Orthology).
MORF4L1	transfac_pro__M01088	DEAF1 (inferredBy_Orthology).
MORF4L1	flyfactorsurvey__Mad_FlyReg_FBgn0011648	SMAD9 (inferredBy_Orthology).
MORF4L1	transfac_pro__M00430	E2F1 (directAnnotation).
MORF4L1	metacluster_126.3	LIN28B; LIN28B (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."